Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11777759 | 0.85 | KEAP1 (0.50) | KEAP1TSHRCES2CES1DCLRE1B | |
| SCHEMBL2923481 | 0.85 | TSHR (0.50) | KEAP1TSHRCES2CES1AGBL2 | |
| SCHEMBL8576783 | 0.82 | KEAP1 (0.55) | KEAP1CES2CES1DCLRE1BKDM4E | |
| SCHEMBL4146826 | 0.82 | KEAP1 (0.55) | KEAP1TSHRCES2CES1DCLRE1B | |
| SCHEMBL22866665 | 0.82 | TSHR (0.45) | KEAP1TSHRCES2CES1AGBL2 | |
| SCHEMBL2395772 | 0.82 | TSHR (0.54) | TSHRAGBL2CXCL8AKR1C3AKR1C2 | |
| SCHEMBL13806627 | 0.81 | KEAP1 (0.53) | KEAP1TSHRCES2CES1DCLRE1B | |
| SCHEMBL150440 | 0.81 | KEAP1 (0.53) | KEAP1TSHRCES2CES1DCLRE1B | |
| SCHEMBL503325 | 0.80 | TSHR (0.53) | TSHRCES2CES1AGBL2CXCL8 | |
| SCHEMBL29459931 | 0.80 | TSHR (0.53) | TSHRCES2CES1AGBL2CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221579-A | PRMT5 inhibitors | 北京望实智慧科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11311528-B2 | Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311528-B2 | Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210052573-A1 | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210052573-A1 | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3768266-A1 | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS | Merck Sharp&Dohme Corp. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019182886-A1 | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-8461107-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| EP-2358682-A2 | ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-08-24 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-100564358-C | The method of a kind of preparation 4-(3, the 4-dichlorophenoxy) piperidines | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | CN | disclosed |
| WO-2009134624-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| CN-100352807-C | substituted piperidine compounds | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-1907968-A | Method for making 4-(3,4-dichlorophenoxy)piperidine | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1633414-A | Compound (I) | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | CN | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | KEAP1 684/4885TSHR 1684/4885CES2 322/4885 |
| US-11311528-B2 | Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors | STING1, MAVS, CGAS | KEAP1 71/4885TSHR 4442/4885CES2 4812/4885 |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | KEAP1 18/4885TSHR 4780/4885CES2 3469/4885 |
| US-20210052573-A1 | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS | STING1, MAVS, CGAS | KEAP1 71/4885TSHR 4442/4885CES2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.